Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer

Open access

Published version of a preprint

Abstract

Significance: The hypoxic microenvironment in solid tumors is known to reduce the efficacy of anticancer treatments in many cancer types, including breast cancer. This study shows hypoxia induces an amino acid transporter, SNAT2, which then causes resistance to antihormone therapy. We show major interplay between genes induced by estrogen receptor and hypoxia. Hypoxia-inducible factor 1α compensates for the loss of expression of estrogen receptor-α (ERα) for maintaining SNAT2 expression under hypoxia or endocrine therapies. SNAT2 overexpression produces complete resistance to antiestrogen therapy in vivo and is induced in tamoxifen resistance, and its expression is associated with poor survival in breast cancer and resistance to endocrine therapy in ERα + luminal B patients. Our findings thus have revealed a previously unidentified mechanism for antiestrogen resistance driven by tumor metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1818521116

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. SLC38A2 (SNAT2), SLC7A5, and SLC1A1 are the hypoxic-induced AA transporters in breast cancer cell lines. Ten breast cancer cell lines (columns) cultured in normoxia and hypoxia and submitted to RNA-seq were arranged by supervised average-linkage hierarchical clustering. Heatmap colors represent relative mRNA expression of the selected AA transporters (rows), with higher (red) or lower (blue) expression in hypoxia compared with normoxia. AA transporters that mediate the uptake of gluconeogenic (G) or ketogenic (KG) essential (E) or nonessential (NE) AAs that enter specific steps of the TCA cycle (α-ketoglutarate, fumarate, oxaloacetate, and pyruvate) were clustered. The black box represents the cluster composed of three AA transporters (SLC1A1, SLC7A5, and SLC38A2) in eight cell lines. S, semiessential; TRN, triple receptor-negative.
Fig. 1. SLC38A2 (SNAT2), SLC7A5, and SLC1A1 are the hypoxic-induced AA transporters in breast cancer cell lines. Ten breast cancer cell lines (columns) cultured in normoxia and hypoxia and submitted to RNA-seq were arranged by supervised average-linkage hierarchical clustering. Heatmap colors represent relative mRNA expression of the selected AA transporters (rows), with higher (red) or lower (blue) expression in hypoxia compared with normoxia. AA transporters that mediate the uptake of gluconeogenic (G) or ketogenic (KG) essential (E) or nonessential (NE) AAs that enter specific steps of the TCA cycle (α-ketoglutarate, fumarate, oxaloacetate, and pyruvate) were clustered. The black box represents the cluster composed of three AA transporters (SLC1A1, SLC7A5, and SLC38A2) in eight cell lines. S, semiessential; TRN, triple receptor-negative.CC BY · PubMed Central
Fig. 2. SNAT2 is a hypoxia-induced gene and is mainly regulated by HIF-1α. (A) Immunoblot of four breast cancer cell lines from different histotypes showing the heterogeneity in basal SNAT2 expression and their response to 48 h of hypoxia. (B) N-linked deglycosylation assay using PNGase in MCF7 cell lysate in normoxia and hypoxia. (C) MCF7 parental and MCF7-HIF1α knockout cells (−/−) were cultured in normoxia (red) or in hypoxia (blue, 0.1% O2) for 8, 24, and 48 h. mRNAs were analyzed by RT-qPCR and normalized to 21% O2. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. Ctrl, control; KO, knockout. (D) Immunoblot validation in the same experiment described above. β-Actin is shown as a loading control. (E) MCF7 parental and MCF7-HIF1α (−/−) cells were transfected with scrambled control or siRNAs against HIF-2α (siHIF2α) or treated with PT2779 (HIF-2α inhibitor, 1 μM) and cultured in normoxia (red) or in hypoxia (blue, 0.1% O2) for 48 h. mRNAs were analyzed by RT-qPCR. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. (F) Immunoblot of SNAT2, HIF-1α, and HIF-2α in the same experiment described above (E). β-Actin is shown as a loading control. Error bars indicate SD. *P < 0.05 vs. 21% O2, **P < 0.01 vs. 21% O2, ****P < 0.0001 vs. 21% O2; one-way ANOVA (n = 3 for all experiments).
Fig. 2. SNAT2 is a hypoxia-induced gene and is mainly regulated by HIF-1α. (A) Immunoblot of four breast cancer cell lines from different histotypes showing the heterogeneity in basal SNAT2 expression and their response to 48 h of hypoxia. (B) N-linked deglycosylation assay using PNGase in MCF7 cell lysate in normoxia and hypoxia. (C) MCF7 parental and MCF7-HIF1α knockout cells (−/−) were cultured in normoxia (red) or in hypoxia (blue, 0.1% O2) for 8, 24, and 48 h. mRNAs were analyzed by RT-qPCR and normalized to 21% O2. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. Ctrl, control; KO, knockout. (D) Immunoblot validation in the same experiment described above. β-Actin is shown as a loading control. (E) MCF7 parental and MCF7-HIF1α (−/−) cells were transfected with scrambled control or siRNAs against HIF-2α (siHIF2α) or treated with PT2779 (HIF-2α inhibitor, 1 μM) and cultured in normoxia (red) or in hypoxia (blue, 0.1% O2) for 48 h. mRNAs were analyzed by RT-qPCR. SNAT2 mRNA was normalized to the mean of β-actin and RPL11. (F) Immunoblot of SNAT2, HIF-1α, and HIF-2α in the same experiment described above (E). β-Actin is shown as a loading control. Error bars indicate SD. *P < 0.05 vs. 21% O2, **P < 0.01 vs. 21% O2, ****P < 0.0001 vs. 21% O2; one-way ANOVA (n = 3 for all experiments).CC BY · PubMed Central
Fig. 3. SNAT2 is up-regulated in vivo by hypoxia. (A) Representative SNAT2 immunostaining in MDA-MB-231 (first row) and MCF7 (second row) xenografts treated with phosphate-buffered saline (PBS; n = 5) or bevacizumab (Beva; n = 5). (Scale bars: 100 μm.) SNAT2 protein expression quantification by ImageJ in the same xenografts is shown. N, necrosis. (B) Representative SNAT2 and CA9 (hypoxia) immunostaining in MDA-MB-231 and MCF7 xenografts treated with bevacizumab, showing colocalization of SNAT2 in hypoxic areas of the tumors. (Scale bars: 100 μm). (C) Xenograft growth curves of MCF7 parental (n = 6) and MCF7-HIF1α KO cells (n = 7). CRTL, control. (D) Representative immunohistochemical images of SNAT2 staining in MCF7 parental and MCF7-HIF1α-o xenografts and a bar chart of scoring. (Scale bars: 100 μm.) Error bars indicate SD. *P < 0.05, ***P < 0.01; nonparametric Mann–Whitney test (n = 5 per group).
Fig. 3. SNAT2 is up-regulated in vivo by hypoxia. (A) Representative SNAT2 immunostaining in MDA-MB-231 (first row) and MCF7 (second row) xenografts treated with phosphate-buffered saline (PBS; n = 5) or bevacizumab (Beva; n = 5). (Scale bars: 100 μm.) SNAT2 protein expression quantification by ImageJ in the same xenografts is shown. N, necrosis. (B) Representative SNAT2 and CA9 (hypoxia) immunostaining in MDA-MB-231 and MCF7 xenografts treated with bevacizumab, showing colocalization of SNAT2 in hypoxic areas of the tumors. (Scale bars: 100 μm). (C) Xenograft growth curves of MCF7 parental (n = 6) and MCF7-HIF1α KO cells (n = 7). CRTL, control. (D) Representative immunohistochemical images of SNAT2 staining in MCF7 parental and MCF7-HIF1α-o xenografts and a bar chart of scoring. (Scale bars: 100 μm.) Error bars indicate SD. *P < 0.05, ***P < 0.01; nonparametric Mann–Whitney test (n = 5 per group).CC BY · PubMed Central
Fig. 4. SNAT2 expression is independently modulated by ERα and HIF-1α, and is up-regulated in a tamoxifen-resistant cell line. (A) RNA-seq and ChIP-seq genome-browser tracks illustrating occupancy of HIF-1α (Top), HIF-2α (Middle), and ERα (Bottom) at the same genomic coordinates on chromosome 12. The same plots for H3K4me3 are shown. Peaks (red box) represent the areas where transcription factors interact with DNA. (B) Western blotting for SNAT2, ERα, HIF-1α, and HIF-2 in MCF-7 and T47D cells treated with 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (C) Confocal microscopy of SNAT2 (green), phalloidin (F-actin, red), and DAPI (blue) in MCF7 in normoxia (N) and hypoxia (H; 0.1% O2) with or without E2 treatment (E; 10 nM) for 24 h. (D) MCF7 cells were grown in a charcoal-stripped, phenol-free medium for 3 d and then incubated with or without fulvestrant (Fulv; 10 μM) and with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (E) MCF7 control and MCF7-HIF1α-o cells were treated with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (F) Representative Western blots of parental (MCF7-par) and MCF7 tamoxifen-resistant cells (MCF7-TamR) cultured in normoxia and hypoxia (0.1% O2) for 48 h. (G) Graph of the effect of MeIAB (10 mM) treatment on MCF7 and MCF7-TamR spheroid growth. Error bars indicate SD. **P < 0.05, ***P < 0.01; two-way ANOVA (n = 4).
Fig. 4. SNAT2 expression is independently modulated by ERα and HIF-1α, and is up-regulated in a tamoxifen-resistant cell line. (A) RNA-seq and ChIP-seq genome-browser tracks illustrating occupancy of HIF-1α (Top), HIF-2α (Middle), and ERα (Bottom) at the same genomic coordinates on chromosome 12. The same plots for H3K4me3 are shown. Peaks (red box) represent the areas where transcription factors interact with DNA. (B) Western blotting for SNAT2, ERα, HIF-1α, and HIF-2 in MCF-7 and T47D cells treated with 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (C) Confocal microscopy of SNAT2 (green), phalloidin (F-actin, red), and DAPI (blue) in MCF7 in normoxia (N) and hypoxia (H; 0.1% O2) with or without E2 treatment (E; 10 nM) for 24 h. (D) MCF7 cells were grown in a charcoal-stripped, phenol-free medium for 3 d and then incubated with or without fulvestrant (Fulv; 10 μM) and with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (E) MCF7 control and MCF7-HIF1α-o cells were treated with or without 10 nM E2 in normoxia and hypoxia (0.1% O2) for 48 h. β-Actin is shown as a loading control. (F) Representative Western blots of parental (MCF7-par) and MCF7 tamoxifen-resistant cells (MCF7-TamR) cultured in normoxia and hypoxia (0.1% O2) for 48 h. (G) Graph of the effect of MeIAB (10 mM) treatment on MCF7 and MCF7-TamR spheroid growth. Error bars indicate SD. **P < 0.05, ***P < 0.01; two-way ANOVA (n = 4).CC BY · PubMed Central
Fig. 5. SNAT2 knockdown sensitizes MCF7 cells to fulvestrant treatment in hypoxia and reduces glutamine intake. (A) Total of 105 cells were seeded in charcoal-stripped medium and treated with or without E2 (10 nM), fulvestrant (10 μM), and SNAT2 knockdown for 5 d in normoxia (N; red) and hypoxia (H; blue, 1% O2) (n = 4). Scr, scrambled control. (B) Glutamine consumption was calculated as reported from cells grown in the experiment above. (C) Determination of mitochondrial membrane potential in MCF7 cells by JC-1 staining in normoxia and hypoxia (0.1% O2, 48 h) with or without SNAT2 knockdown and with or without fulvestrant (Fulv; 10 μM). Values in the trapeziform regions indicate the proportion of cells compared with the total number of cells. The percentage of depolarized green mitochondria is shown in the R2 box. (A–C) *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05 (compared with Fulv treatment) by χ2 test compared with controls (n = 3). (D) Representative plot of O2 consumption with or without SNAT2 knockdown with or without Fulv (10 μM) in normoxia (21% O2). *P < 0.05, **P < 0.01, #P < 0.05 (compared with Fulv treatment); unpaired t test (n = 3). Ant, antimycin A; Ctrl, control; FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; OCR, oxygen consumption rate; Rot, rotenone.
Fig. 5. SNAT2 knockdown sensitizes MCF7 cells to fulvestrant treatment in hypoxia and reduces glutamine intake. (A) Total of 105 cells were seeded in charcoal-stripped medium and treated with or without E2 (10 nM), fulvestrant (10 μM), and SNAT2 knockdown for 5 d in normoxia (N; red) and hypoxia (H; blue, 1% O2) (n = 4). Scr, scrambled control. (B) Glutamine consumption was calculated as reported from cells grown in the experiment above. (C) Determination of mitochondrial membrane potential in MCF7 cells by JC-1 staining in normoxia and hypoxia (0.1% O2, 48 h) with or without SNAT2 knockdown and with or without fulvestrant (Fulv; 10 μM). Values in the trapeziform regions indicate the proportion of cells compared with the total number of cells. The percentage of depolarized green mitochondria is shown in the R2 box. (A–C) *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05 (compared with Fulv treatment) by χ2 test compared with controls (n = 3). (D) Representative plot of O2 consumption with or without SNAT2 knockdown with or without Fulv (10 μM) in normoxia (21% O2). *P < 0.05, **P < 0.01, #P < 0.05 (compared with Fulv treatment); unpaired t test (n = 3). Ant, antimycin A; Ctrl, control; FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; OCR, oxygen consumption rate; Rot, rotenone.CC BY · PubMed Central
Fig. 6. SNAT2 expression is related to poor outcomes in endocrine-treated breast cancer patients. (A) Xenograft growth curves of MCF7 parental and SNAT2-o clones ± bevacizumab (BEV) or ± fulvestrant (FULV) treatment. CTL, control. ***P < 0.001, **P < 0.01, *P < 0.05; linear regression followed by Student’s t test (n = 5). (B) Kaplan–Meier plot for patients from the TGCA breast cancer invasive cohort (ALL and ER+ cohorts) stratified according to the expression of SNAT2 mRNA expression (T1, lower tertile; T2, middle tertile; T3, upper tertile). Overall survival (OS) was evaluated. The graph shows that high tumor SNAT2 levels are associated with increased patient mortality. Subanalysis based on tertile expression showed that the higher SNAT2 mRNA expression (upper tertile) cohort has a lower survival compared with the lower tertile cohort (T3 vs. T1). HR, hazard ratio. (C) Kaplan–Meier plots for luminal A and B ER+ breast cancer patients (Left) and for same subgroups that received endocrine [aromatase inhibitor (AI) or tamoxifen (TAM), Center] or tamoxifen only (Right). Patients were stratified according to the expression of SNAT2 mRNA [above (red) versus below (black) third quartile]. Recurrence-free survival was evaluated.
Fig. 6. SNAT2 expression is related to poor outcomes in endocrine-treated breast cancer patients. (A) Xenograft growth curves of MCF7 parental and SNAT2-o clones ± bevacizumab (BEV) or ± fulvestrant (FULV) treatment. CTL, control. ***P < 0.001, **P < 0.01, *P < 0.05; linear regression followed by Student’s t test (n = 5). (B) Kaplan–Meier plot for patients from the TGCA breast cancer invasive cohort (ALL and ER+ cohorts) stratified according to the expression of SNAT2 mRNA expression (T1, lower tertile; T2, middle tertile; T3, upper tertile). Overall survival (OS) was evaluated. The graph shows that high tumor SNAT2 levels are associated with increased patient mortality. Subanalysis based on tertile expression showed that the higher SNAT2 mRNA expression (upper tertile) cohort has a lower survival compared with the lower tertile cohort (T3 vs. T1). HR, hazard ratio. (C) Kaplan–Meier plots for luminal A and B ER+ breast cancer patients (Left) and for same subgroups that received endocrine [aromatase inhibitor (AI) or tamoxifen (TAM), Center] or tamoxifen only (Right). Patients were stratified according to the expression of SNAT2 mRNA [above (red) versus below (black) third quartile]. Recurrence-free survival was evaluated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 131

Metadata

Authors
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., Teoh, E. J., Cheng, W.-C., Lord, S., Anastasiou, D., Haider, S., McIntyre, A., Goberdhan, D. C. I., Buffa, F., & Harris, A. L.
Affiliations
  • Cancer Research UK (GB)
  • King Abdulaziz University (SA)
  • John Radcliffe Hospital (GB)
  • The Francis Crick Institute (GB)
  • University of Oxford (GB)
  • Institute of Cancer Research (GB)
  • University of Nottingham (GB)
  • University of California San Diego (US)
Corresponding author
  • Morotti, Matteo
  • Harris, Adrian L.
Venue
Proceedings of the National Academy of Sciences
Published
2019-05-31
Volume
116
Issue
25
Pages
12452-12461
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2885171918
Cited by
131
References
83
Citations by year
2026: 10 · 2025: 17 · 2024: 24 · 2023: 14 · 2022: 17 · 2021: 27 · 2020: 20 · 2019: 2
FWCI
5.22
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • Archivio istituzionale della Ricerca - Bocconi (submittedVersion)
  • The Francis Crick Institute
Funders
  • Breast Cancer Research Foundation (BCRF-17-064)
  • Fondazione Umberto Veronesi (2018)
  • Cancer Research UK (ANR00163)
  • Oxford NIHR Biomedical Research Centre (2018)
  • Oxfordshire Community Foundation (8297)
  • Friends of Kennington Cancer Fund (2018)
  • RCUK | Medical Research Council (MC_UP_1202/1)
  • Francis Crick Institute (FC001033)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
SNAT2, SLC38A2, breast cancer, hypoxia, endocrine therapy resistance, estrogen receptor alpha, HIF-1α, glutamine transport, fulvestrant, antiestrogen therapy, anti-VEGF therapy, tumor hypoxia, drug resistance
MeSH terms
Animals, Breast Neoplasms, Female, Humans, Cell Hypoxia, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Estrogen Receptor Modulators, Amino Acid Transport System A, Cell Line, Tumor, Estrogen Receptor alpha, Mice, Tumor Microenvironment, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. https://app.cochat.ai/papers/10.1073/pnas.1818521116
The paper
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., Teoh, E. J., Cheng, W.-C., Lord, S., Anastasiou, D., Haider, S., McIntyre, A., Goberdhan, D. C. I., Buffa, F., & Harris, A. L. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1818521116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.